104 completed, 79 unknown, 26 terminated, 8 recruiting. 80 Phase 4, 60 Phase 2, 33 Phase 3, 25 Phase 1, 24 Not applicable.
Follow entecavir: new trials by email Literature Review of entecavir trials Research Report on entecavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response TQA3605 tablets Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 930 | 2026-09-01 | 2026-10-02 |
| Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP Chidamide, Entecavir Tablets - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Ou Bai, MD/PHD | 200 | 2026-05-30 | 2026-03-25 |
| Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide Entecavir, Tenofovir Disoproxil Fumarate（TDF）, Tenofovir alafenamide（TAF） - Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction) | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 64 | 2026-03-15 | 2026-08-13 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 80 | 2026-01-11 | 2026-01-16 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 60 | 2026-01-11 | 2026-01-16 |
| Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver Entecavir - Hepatitis B | Phase 4 | Recruiting | Bangladesh Medical University | 48 | 2026-01-01 | 2026-09-11 |
| TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma The arm will receive combination therapy (entecavir 0.5 mg once daily plus TAF 25 mg once daily); after HBV DNA becomes undetectable, the combination group will switch to TAF monotherapy., TAF monotherapy - Hepatitis B, Hepatocellular Carcinoma (HCC) | Not applicable | Not yet recruiting | Sun Yat-sen University | 120 | 2025-12-01 | 2025-11-28 |
| Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors Entecavir, HBIG, EVLP UV Light Treatment - Hepatitis B Virus (HBV), Lung Transplant Recipient | Phase 4 | Recruiting | University Health Network, Toronto | 20 | 2025-09-24 | 2025-11-17 |
| Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy Entecavir (ETV), Zinc (zinc sulphate) - Liver Fibroses, HBV (Hepatitis B Virus) | Phase 2 | Not yet recruiting | Tanta University | 44 | 2025-09-01 | 2025-08-28 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects TQA3605 tablets Placebo, TQA3605 Tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 2 | Withdrawn | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-07-09 | 2025-08-03 | |
| Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers Entecavir - Gastrointestinal Cancers | Phase 3 | Recruiting | Sun Yat-sen University | 136 | 2025-05-15 | 2025-05-11 |
| ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection Anti-PD-L1 antibody (ASC22), Nucleotide analogs, Peg-IFNα - Chronic Hepatitis b | Phase 4 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2024-05-21 | 2026-09-01 |
| A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis b | Phase 1 / Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 | 2023-12-07 | 2024-11-14 |
| HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV Bulevirtide - Hepatitis D | Unknown | University of Athens | 80 | 2023-05-01 | 2023-07-03 | |
| Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B Nuc Discontinuation, Entecavir or Tenofovir - Chronic Hepatitis b | Not applicable | Active not recruiting | E-DA Hospital | 360 | 2022-12-20 | 2023-03-31 |
| A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB ZM-H1505R, ZM-H1505R placebo, Baraclude - Hepatitis B, Chronic | Phase 2 | Unknown | Shanghai Zhimeng Biopharma, Inc. | 90 | 2022-11-11 | 2023-05-08 |
| A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF) - Hepatitis B, Chronic | Early Phase 1 | Withdrawn | Janssen Pharmaceutica N.V., Belgium | 2022-10-31 | 2025-06-25 | |
| Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide - Lung Transplant, Hepatitis B | Phase 2 | Withdrawn | University of Pennsylvania | 2022-09-06 | 2024-08-06 | |
| Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir Tenofovir alafenamide, Entecavir - Chronic Hepatitis B | Active not recruiting | Chinese University of Hong Kong | 1800 | 2022-09-01 | 2023-02-08 | |
| The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection P1101 + Nivolumab + Entecavir - Chronic Hepatitis B Infection, Chronic Hepatitis D Infection | Phase 1 | Completed | PharmaEssentia | 20 | 2022-08-17 | 2026-06-10 |
Showing 20 of 233. Sign in to see all of them.
Hepatitis B, Chronic (139) · Hepatitis B (82) · Carcinoma, Hepatocellular (11) · Liver Cirrhosis (11) · Hepatitis (5) · Acute-On-Chronic Liver Failure (3) · Chronic Disease (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Arthritis, Rheumatoid (2) · Bronchiolitis Obliterans Syndrome (2) · DNA Virus Infections (2) · Fibrosis (2) · Hepatitis D (2) · Hepatitis, Chronic (2)
Bristol-Myers Squibb (27) · Sun Yat-sen University (12) · Assembly Biosciences (8) · Third Affiliated Hospital, Sun Yat-Sen University (8) · Arrowhead Pharmaceuticals (7) · National Taiwan University Hospital (7) · Asan Medical Center (6) · Beijing Friendship Hospital (6) · Hoffmann-La Roche (6) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (5) · Janssen Research & Development, LLC (5) · Yonsei University (5) · Enyo Pharma (4) · Foundation for Liver Research (3) · Nanfang Hospital, Southern Medical University (3)
China (95) · South Korea (43) · Taiwan (38) · United States (33) · Canada (21) · Hong Kong (20) · Australia (16) · Poland (16) · Germany (15) · New Zealand (15) · Italy (14) · United Kingdom (13) · France (12) · Turkey (Türkiye) (11) · Russia (9)
Liang Peng, Doctor (5) · Hong You, Doctor (3) · Jia-Horng Kao, MD, PhD (3) · Jun Yong Park, M.D (3) · Sang Hoon Ahn, M.D.Ph.D (3) · Averell Sherker, MD (2) · Chen-Hua Liu, MD (2) · Cheng-Chao Liang, MD (2) · Chih-Lin Lin, MD (2) · Ching-Sheng Hsu, MD (2) · Hyung Joon Yim, M.D. (2)
PMID 33460002, PMID 25447852, PMID 25514302, PMID 16525138, PMID 28427875, PMID 30876946, PMID 34843068, PMID 39373164, PMID 10613747, PMID 15470215, PMID 15565615, PMID 15985009, PMID 16164651, PMID 16525137, PMID 16879891, PMID 17302367, PMID 17377504, PMID 18808318, PMID 19052126, PMID 19223649, PMID 20028815, PMID 20091678, PMID 20220333, PMID 2023605, PMID 21254162, PMID 2142748, PMID 21677438, PMID 22233350, PMID 22371643, PMID 22643350, PMID 22668640, PMID 23150796, PMID 23449768, PMID 23650172, PMID 23689577, PMID 23732715, PMID 23775967, PMID 23876210, PMID 24189358, PMID 24375637, PMID 24583931, PMID 24787673, PMID 24915612, PMID 25168842, PMID 25190434, PMID 25348661, PMID 25476749, PMID 25596179, PMID 25800784, PMID 25814467
2009 (3), 2014 (3), 2019 (3), 2017 (2), U01DK082843 (2), U01DK082864 (2), U01DK082871 (2), U01DK082874 (2), U01DK082916 (2), U01DK082944 (2), UL1TR000004 (2), 2008 (1), 2015 (1), 2023 (1), M01RR000040 (1)